Cosmos Health Files Patent for CCX0722 Hydrogel in U.S., Europe, Australia, Canada
COSM•Cosmos Health’s subsidiary Cana Laboratories advanced patent application WO2025108566A1 for its CCX0722 hydrogel into the U.S., European regional phase, Australia and Canada, granting full IP ownership without royalties. Global weight management market hit $190.6 billion in 2025, forecast to grow at 14.2% CAGR to $562.2 billion by 2033, boosting commercialization potential.
1. Patent Advancement Details
Cosmos Health's subsidiary Cana Laboratories advanced international patent application WO2025108566A1, titled "Hydrogel for Body Weight Management," into the U.S. national phase, European regional phase, Australia and Canada. This step follows Cana's acquisition of the application from Cloudpharm, granting Cosmos full IP ownership of CCX0722 without royalty obligations.
2. CCX0722 Mechanism and Development Timeline
CCX0722 is a non-absorbed hydrogel capsule that swells over 100-fold in the stomach to promote satiety, then passes naturally through the GI tract. Developed since late 2022, the platform completed formulation optimization by mid-2023, pilot scale-up by July 2024 and entered final development phase in February 2025.
3. Market Impact and Strategic Significance
The global weight management market reached $190.6 billion in 2025 and is projected to grow at a 14.2% CAGR to $562.2 billion by 2033. Owning the CCX0722 IP outright positions Cosmos Health to pursue licensing, co-development and strategic partnerships across major healthcare markets via its GMP-certified manufacturing platform.
